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Agitation is a heterogeneous concept without a uniformly accepted definition, however, 
it is generally considered as a state of cognitive and motor hyperactivity characterized 
by excessive or inappropriate motor or verbal activity with marked emotional arousal. 
Not only the definition but also other aspects of agitated patients’ care are still unsolved 
and need consensus and improvement. To help the discussion about agitation among 
experts and improve the identification, management, and treatment of agitation, the 1st 
International Experts’ Meeting on Agitation was held in October 2016 in Madrid. It was 
attended by 20 experts from Europe and Latin America with broad experience in the 
clinical management of agitated patients. The present document summarizes the key 
conclusions of this meeting and highlights the need for an updated protocol of agitation 
management and treatment, the promotion of education and training among healthcare 
professionals to improve the care of these patients and the necessity to generate clinical 
data of agitated episodes.
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iNTRODUCTiON
Patients with acute psychomotor agitation are commonly attended in medical and psychiatric clini-
cal settings. Agitation is a heterogeneous concept without a uniformly accepted definition; however, 
it is generally considered as a state of cognitive and motor hyperactivity characterized by excessive 
or inappropriate motor or verbal activity with marked emotional arousal (1–3). While it is difficult 
to estimate the prevalence of acute agitation episodes due to the scarcity of epidemiological studies, 
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it is widely recognized that agitation is a common phenomenon, 
both in medical and psychiatric emergency and inpatient settings. 
Acute episodes of psychomotor agitation account for 900,000 
annual visits to psychiatric emergency services (4) and represent 
a total of 1.7 million emergency department visits per year in the 
USA (5). Furthermore, it is estimated that up to 10% of psychiat-
ric emergencies attended at emergency services involve an acute 
agitation episode (6–8). Agitation is frequently associated with 
an underlying psychiatric disorder, particularly schizophrenia, 
bipolar disorder, personality disorders, Alzheimer’s disease, or 
other types of dementia, among others (6, 9, 10). In cases of 
dementia, there are multiple factors that can precipitate or worsen 
psychomotor agitation, such as medical problems, drug adverse 
events, sleep abnormalities, delirium, depression, or environmen-
tal and social factors, but it is mostly linked to the severity of the 
neurocognitive disorder (11). Treatment of the agitated patient 
is complex, due to the status of the patient, the involvement of 
multiple healthcare professionals (HCPs), and the ethical/legal 
concerns on the different management procedures.
Various guidelines are available providing guidance on the 
medical and psychiatric assessment and the pharmacological 
and non-pharmacological management of the patient presenting 
with an episode of agitation, including the recent guidelines from 
Austrian Society for Neuro-Psychopharmacology and Biological 
Psychiatry (12), the recommendations from the World Federation 
of Societies of Biological Psychiatry (WFSBP) regarding manage-
ment of acute agitation in schizophrenia (13), the Project BETA 
(Best practices in Evaluation and Treatment of Agitation) guide-
lines from the American Association for Emergency Psychiatry 
(2, 14–17), the Clinical Policy for Diagnosis and Management 
of the Adult Psychiatric Patient in the Emergency Department 
from the American College of Emergency Physicians’ (18), 
the guideline for Violence: the short-term management of 
disturbed/violent behavior in inpatient settings and emergency 
departments—CG25—issued by the United Kingdom National 
Institute for Health and Care Excellence (NICE) in 2005 (19) or 
the standards in Restraint and Seclusion proposed by the Joint 
Commission on Accreditation of Healthcare Organizations and 
the Centers for Medicare and Medicaid (20). In addition, the 
Expert consensus paper on the assessment management of agita-
tion in psychiatry from the WFSBP has recently compiled the 
state-of-art of the assessment and management of agitation (21). 
In spite of all these guidelines, care of the agitated patient remains 
often suboptimal, partly as a result of the failure to implement 
updated consensus recommendations and treatment algorithms, 
and partly due to the heterogeneous etiology and complexity of 
the clinical presentation of the episode of agitation. An agreement 
for clearer patient-centered protocols that can be followed by all 
HCPs involved in the management of agitated patients in any 
clinical setting is an important unmet need.
A group of 20 experts from nine different countries across 
Europe and South America with an interest and large experience 
in the clinical management of agitated patients met in Madrid 
for the 1st International Experts’ Meeting on Agitation. This 
independent expert panel was set up to identify the difficulties 
and barriers HCPs face in daily clinical practice in the assess-
ment and management of agitated patients in emergency and 
inpatient settings and to discuss practical recommendations to 
best improve them. Timely evaluation of precipitating factors and 
a prompt intervention are crucial to prevent escalation to violent 
behaviors and potentially dangerous situations. The objectives 
of the expert meeting and the present document is to increase 
awareness on the adequate assessment, early identification and 
on the optimal and most efficient individualized therapeutic 
interventions of an episode of agitation. The key topics addressed 
in this statement are as follows: (1) definition and identification 
of agitation, (2) current management practices of an episode of 
agitation, (3) ideal treatment interventions, and (4) current barri-
ers and potential solutions for better management and treatment 
practices of agitated patients.
MeTHODS
The present document is the result of a full-day meeting held in 
October 2016 in Madrid in which the need for improved com-
munication and a practical consensus statement were identified. 
The meeting was attended by 20 Psychiatry experts actively 
involved in the clinical management of agitated patients from 
Argentina, Austria, Finland, France, Germany, Greece, Italy, 
Norway, Spain, and Sweden. The meeting was organized in dif-
ferent sections, where participants had the opportunity to discuss 
different concepts in groups using Workmats® (22) and then 
shared the results with the rest of the groups to start a debate and 
reach conclusions. Workmat® methodology consists in exercises 
presented in a poster format designed to maximize the interac-
tion among participants and sharing of ideas to reach agreements 
and conclusions on a specific subject (22). The present document 
that has been reviewed and discussed within the expert group is 
the result of the debates during the meeting and the exchange of 
information and proposals prior and after the meeting. Following 
this process, the final document was circulated for written 
approval by all members of the Expert Group. For the prepara-
tion of the document, non-systematic search for clinical studies, 
randomized controlled trials, and reviews was performed from 
Medline, as well as from cross-referencing and identification by 
the participating experts. Details of the clinical presentation, 
assessment, and management of agitated patients were further 
informed by clinical expertise. Results and conclusions shown 
here represent the general views agreed by the experts group for 
episodes of agitation. Regarding the treatment, the discussion 
focused primarily on the pharmacological options. This practical 
consensus statement is written for specialists in psychiatry but 
is also intended to increase the understanding of acute agitation 
episodes from other healthcare providers.
KeY ReSULTS AND CONCLUSiON
Definition and identification of 
Psychomotor Agitation
There is no consensus on the definition of agitation and on what 
elements should be included in this clinical entity. Moreover, the 
identification of agitation and the assessment of potential escala-
tion of symptoms are still a matter of controversy. Therefore, the 
FigURe 1 | Agreed current and ideal acting-point for healthcare professional (HCPs) and patients/caregivers.
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first exercise during the expert meeting was to develop a defini-
tion of agitation that could allow specialized and non-specialized 
HCPs to identify an agitation episode at an early stage. The expert 
discussion consisted in choosing, from an open list, the signs and/
or symptoms that would better help identify psychomotor agita-
tion to specialized and non-specialized HCPs.
The group concluded that alterations in physical parameters 
may be useful but they have limited relevance in differentiating 
agitation from other pathological states. Cognitive alterations 
have also limited practical use. By contrast, behavioral symp-
toms were found to be relevant in order to quickly identify 
episodes of agitation and even though further assessment may 
provide a definitive diagnosis, the following four signs were 
identified as helpful to provide a preliminary identification of 
agitation:
1. Inability to stay calm or still,
2. Motor and verbal hyperactivity and hyperresponsiveness,
3. Emotional tension,
4. Difficulties in communication.
Following the discussion during this initial exercise, agitation 
was defined as “A state where patients cannot remain still or calm, 
characterized by internal features such as hyperresponsiveness, 
racing thoughts and emotional tension; and external ones, mainly 
motor and verbal hyperactivity, and communication impair-
ment.” It was recognized that while this definition may not be 
the most inclusive and accurate, it has a practical component that 
may sacrifice some scientific precision for increased applicability. 
However, the identification process relays, at least partly, on the 
experience of the HCPs facing the patient and the general feeling 
that the patient is agitated. This is a work-in-progress definition 
that needs to be validated due to the complexity of agitation and 
the many different levels of severity and presentations that can 
be found.
Management of Psychomotor Agitation
Agitation is a dynamic situation that may rapidly escalate 
from mild (distress, restless, worry, fear, etc.) to loss of control 
(violence, aggressiveness, confusion, etc.) and different scales 
have been developed to measure the severity of agitation (2, 21, 
23–25). Given the continuum clinical presentation of agitation, it 
may be often difficult to identify the best moment for intervening 
in order to optimize the patients’ outcome. During this discussion 
process, experts had to define both: their current acting-point 
during an episode of agitation and the ideal acting-point (for 
HCPs and also for patients) based on a curve representing time in 
the X axis and the Positive and Negative Syndrome Scale-Excited 
Component (26) in the Y axis (Figure 1).
The group agreed that intervention aimed at avoiding the 
“point of no return,” where escalation cannot be controlled only 
by non-pharmacological interventions, but the exact moment 
was controversial. The current acting-point in clinical practice 
for the panel participants was right before reaching levels of a 
severe degree of agitation. In addition, it was acknowledged that 
pharmacological treatment is usually avoided or postponed in 
the presence of mild stages of agitation because (I) the episode 
may de-escalate without further treatment, (II) patients or their 
caregivers prefer avoiding medication or (III) non-pharmaco-
logical treatments, such as verbal de-escalation, are considered 
the first-choice at that stage. During the discussion, the experts 
agreed that it would be beneficial to intervene as early as possible, 
between the low-moderate to mid-moderate level of severity. This 
would reduce the chances of escalation and would improve the 
patient cooperativeness and final clinical outcome. Moreover, 
when experts considered the preference of patients and caregiv-
ers, the gap was even larger, as the preferred ideal intervention 
point was situated in the mild levels of severity (Figure 1). To 
improve the patient experience and avoid escalation of symp-
toms, intervention should be considered earlier, probably before 
reaching moderate levels of agitation. This would improve patient 
TAbLe 1 | Benefits and risks of an earlier intervention during an episode of 
agitation.
Benefits Broader set of intervention choices, both pharmacological and 
non-pharmacological
Patient cooperation
Less traumatic/invasive treatments
Increased therapeutic alliance
Potentially, reduced waiting time until a full diagnosis can be made
Reduction of medical and economic resources needed
Drawbacks Agitation misidentification
Safety issues due to the use of drugs that could have been avoided
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cooperation, and consequently would allow using less invasive/
traumatic treatments. The benefits of an early intervention are 
clearly superior to the risks (Table 1), thus earlier intervention 
was strongly recommended.
Pharmacological Treatment  
of Psychomotor Agitation
Due to the diversity of underlying causes of agitation and the 
different degrees of severity, choice of best treatment option 
is not always easy. In general, it was acknowledged by the 
expert group that there are two main trends to treat agitated 
patients. (I) “Imposing treatment,” which tends to occur when 
the psychiatrist is not familiar with the patient (seen for the 
first time) or in episodes of severe agitation. It includes more 
coercive interventions and invasive treatments such as intra-
muscular medications and (II) “Proposing treatment,” which 
occurs more commonly when the psychiatrist is familiar 
with the patient or in cases of mild agitation. It includes less 
intrusive management, such as verbal de-escalation, usually 
leading to patient cooperation and, if pharmacological treat-
ment is needed, less invasive options can be proposed to the 
patient, such as oral or inhaled medications. During one of the 
exercises, the participants were asked to state the approximate 
frequency of use of the different pharmacological options. 
Despite the fact that there was a large variety of choices 
depending on the different countries, or even depending on 
the various clinical settings, in general, antipsychotics (APs) 
were the most frequently used (more than 50%); followed by 
benzodiazepines (BZD), and just a few participants used other 
choices such as anti-depressants, anti-histamine medications, 
so on. Within the APs, oral and intramuscular formulations 
were currently the preferred ones, leaving the other formu-
lations as second choices. Inhaled APs were still not com-
monly used, although there was a trend toward increasing 
their use.
During the session, experts focused on the characteristics 
of a hypothetical ideal pharmacological treatment for agitation 
and, despite the differences in available pharmacological options 
in each setting, which of the current available treatments were 
positioned closest to the ideal. The different characteristics, 
described in the consensus (21), were presented to the partici-
pants and they had to score each route of administration from 
1 to 10 (with 10 being closest to the ideal treatment) based on 
available data from studies in the literature and on the perception 
and experience of the participants. The characteristics evaluated 
were as follows:
•	 Rapid onset of action,
•	 Calmness without sedation,
•	 Easy to administer,
•	 Non-invasive,
•	 Non-traumatic/non-coercive,
•	 Safety profile,
•	 Favorable tolerability,
•	 Patient preference,
•	 Promote long-term adherence to treatment of the underlying 
condition.
Interestingly, three different treatment groups emerged based 
on the overall characteristics profile (Figure 2):
•	 Intramuscular and intravenous AP formulations: both 
routes of administration were acknowledged to have similar 
profiles, scoring high in rapidness of action but relatively low 
in the rest of therapeutic properties. This was of particular 
relevance for the patient, due to their coercive and invasive 
nature.
•	 Oral and sublingual AP formulations: Both routes of 
administration scored very similar for all the features, with 
high scores for ease of administration, non-invasive, and 
non-traumatic characteristics but scoring below average for 
rapidness of action and in calming without sedation.
•	 Inhaled AP formulation: this represents a different treatment 
option based on the characteristic profile, with very rapid onset 
of action and calming without sedating as the key features. 
Inhaled AP were identified as having combined positive features 
of the two other groups, similar rapidness as the intramuscular 
and intravenous formulations, and similar non-invasive/trau-
matic, safety/tolerability, and patient preference characteristics 
to the oral and sublingual formulations. In addition, regarding 
the capacity of calming without sedating, the inhaled AP for-
mulation was rated significantly higher than the rest.
During the discussion, all the therapeutic characteristics 
were considered as having similar weight. Consequently, there 
was limited debate on which of the different features were more 
relevant for the selection of a pharmacological treatment of 
agitation. There was also some discussion on whether treatment 
decisions should be made based only on a limited number of 
characteristics. During the debate, a rapid onset of action, calming 
without sedating and convenience (including ease to administer, 
non-invasive/traumatic) were the features that occupied more 
time during the discussion.
In conclusion, according to this exercise, inhaled APs have 
characteristics that would be more similar to an ideal treatment, 
with a rapid onset of action, calming without sedating effects and 
being non-invasive/traumatic. However, as identified by expert 
participants, use of these inhaled APs in daily clinical practice 
remains very low compared to other formulations, partly due 
to limited experience, knowledge of the product or inertia from 
previous practices. One of the potential limitations of these 
conclusions was that the exercise only evaluated individual 
FigURe 2 | Spidermap of different antipsychotic (AP) formulations based on the average score for each one of the different characteristics, as resulted from the 
session.
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treatments and did not consider potential combinations of dif-
ferent medications.
barriers and Solutions for the effective 
Management and Treatment of Agitation
During the session, experts were able to discuss the most relevant 
barriers to reach optimal procedures in the care of the acute 
agitated patient and provide solutions to improve the current 
management. Some barriers were presented to participants and 
they could add further suggestions as needed. It became clear 
that most of the barriers were linked and interconnected to each 
other. Three main categories were identified as the main barriers 
to improve agitation care (Figure 3): Lack of protocol/guidelines 
(including guidelines to identify agitation), below optimal 
education/training, and limited clinical data. In parallel with the 
barriers, the solutions that were suggested could also be grouped 
under the same three categories.
Elaboration of a Protocol/Guideline for Agitation
Some of the barriers were related to the difficulty of identifica-
tion, the know-how, or the lack of a clear decision-making 
algorithm. Most of the experts agreed that the elaboration of an 
updated management/treatment algorithm would be a high 
priority; this would help state clear indications for specialists 
and other HCPs in terms of identification, management, and 
treatment. Furthermore, this would also help to standardize 
procedures, moving away from deeply in rooted suboptimal 
practices, and to train clinicians in emergency room and 
hospital medical teams. The specific benefits would include 
an earlier intervention, use of closer-to-ideal treatments, 
improvement of therapeutic alliance, and optimization of 
hospital resources.
Education/Training
Another set of the key barriers were related to the lack of specific 
training programs for HCPs and teams for the management and 
treatment of agitation. Two components were acknowledged as 
necessary to improve agitation outcomes: (I) a basic educational 
program for HCPs involved in the management of agitation, 
aiming to improve the abilities in identifying (symptoms, 
level of severity, etc.) and on how to approach agitation (non-
pharmacological treatments, APs, BZDs, characteristics of the 
different formulations, physical restraint when needed, etc.), 
based on current practices and clinical and evidence-based 
FigURe 3 | Main barriers for the improvement in the management and treatment of agitation grouped by category.
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data, and (II) improved training programs to prepare for the 
practical situations of dealing with an agitated patient in the 
specific settings, which should include training on verbal de-
escalation, strategies to improve the therapeutic alliance, such 
as intervening earlier, more rapidly and in a respectful/ethical 
manner, practical lessons on the use of available treatment 
tools, etc. It was agreed that it is very important to conduct the 
training in a collaborative environment to reach a multidisci-
plinary approach and improve coordinated and collaborative 
teamwork.
Research/Clinical Data
Evidence-based clinical data are published continuously. There-
fore, frequent review of the literature to update guidelines and 
safety information was acknowledged as being highly important. 
In addition, clinical data from each hospital database/registry are 
also relevant to understand how efficient the management and 
treatment of agitation is. Without proper record forms of patients 
with agitation (electronic format is highly recommended), there 
will be a lack of real-world evidence to make decisions and 
progressively optimize and update guidelines locally. The expert 
group agreed as well that clinical data (from clinical trials or from 
centers’ databases) are also relevant to address issues related to 
comorbidities or other patient characteristics (e.g., age, gender, 
medical conditions, and so on), which would allow a more per-
sonalized treatment protocol.
DiSCUSSiON
Episodes of psychomotor agitation represent a significant chal-
lenge in the emergency department and inpatient settings, both 
for non-psychiatric and psychiatric clinical staff, as well as for 
patients and caregivers. Furthermore, agitation and most of the 
interventions and treatment strategies have consequences beyond 
the actual episode. Management of agitation has been associated 
with greater use of healthcare resources, increased length of 
inpatient stay, more hospital readmissions, and higher medica-
tion use, as well as raised burden and management costs (27–29). 
Therefore, one of the conclusions and agreements reached at this 
expert consensus meeting was recognizing the need of improv-
ing interaction, collaborative work, discussion, and agreements 
among experts involved in the management of patients with 
episodes of psychomotor agitation in order to share clinical 
experiences, and address and solve unmet needs. Furthermore, 
FigURe 4 |Action plan to reduce current barriers and  optimize the procedures and interventions for managing the agitated patient.
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participants acknowledged the opportunity to discuss with 
colleagues from other settings and countries the experiences, 
difficulties, barriers, as well as commonalities and disparities in 
the different approaches in daily practice for managing episodes 
of psychomotor agitation in various clinical settings. It was also 
an opportunity to discuss local and international guidelines, 
and best clinical practice recommendations available locally or 
internationally to aid in the management of the agitated patient 
(2, 14–17, 21, 30).
In daily clinical practice, the three aspects that were discussed 
by the expert group, namely early identification, adequate 
management, and pharmacological treatment of agitation, are 
tightly intertwined. Thus, improvement of one of these areas 
may have a positive impact on the other ones. The potential for 
agitation to escalate into aggressive behavior, putting patients, 
staff, and others at risk, highlights the importance to address the 
behavior early, rapidly, and efficiently relying on the most ade-
quate and effective pharmacological and non-pharmacological 
interventions for each patient to ensure the safety of everyone 
involved (6, 31). At the meeting, some solutions were identified 
by the expert participants to reduce the current barriers and, 
consequently, optimize the procedures and interventions for 
managing the agitated patient. However, such potential solu-
tions did not target directly these three aspects of agitation but 
rather proposed more practical solutions that could be imple-
mented in the day-to-day practice. An action plan is presented 
here (Figure 4) based on the discussion of the solutions at the 
meeting.
During the meeting, the workgroup agreed that it would 
be highly recommendable for the appropriate management 
of agitation to rely on standardized protocols at each center, 
particularly so, as treatment protocols and guidelines are com-
monly regarded as gold standards of care. In this context, an 
example of the updated treatment algorithm from the Hospital 
Clinic of Barcelona was presented and discussed (32). Such 
algorithm may be used as a starting point and adapted to each 
specific center. This would help the different members of multi-
disciplinary teams involved in the assessment and management 
of agitated patients to have a clearer understanding of the 
procedures to follow. Having standardized protocols would also 
help educate, train, and engage non-specialized and new staff in 
the early identification and management of the agitated patient. 
Since any protocol would have multiple decision choices, it is 
very important to keep track of the different procedures, so 
that the efficiency of each one can be measured. This would 
also provide evidence to guide any needed amendment to the 
original protocol.
The following strategic triad is highly relevant to advance 
the understanding of the most adequate management of agita-
tion. The relevance lies on the continued improvement of the 
working flow: standardized protocols will improve an adequate 
assessment process, including methods of identification, manage -
ment, and treatment of agitation. This will improve educational 
and training tools that will make a more efficient individual 
and team work possible. Standard procedures and trained 
professionals would allow an accurate registry of the agitation 
cases and analysis of the optimal actions. And closing the 
circle, this analysis will help improving the current protocols 
and algorithms, making possible a working method design that 
will allow updated optimal care of the agitated patient. This 
working plan requires some time and effort but may provide 
great improvements in the experience for patients, caregivers, 
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and HCPs in the management of an episode of agitation, as well 
as a more efficient use of the economic and personal resources 
at each individual center.
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